Clinical trials: Allogeneic Stem-Cell Transplant
Multiple Myeloma, Plasma Cell Leukemia
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Standard therapy for multiple myeloma (MM) usually includes an autologous bone marrow stem cell transplant - a procedure where the patient is treated with high dose chemotherapy and then their own (autologous) stem cells are…
- Trial name
- NCT00615589
- Testing
- Fludarabine/Busulfan x 4 days, stem cell transplant
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
This study aim is to assess, if treosulfan pharmacokinetics are influenced by declined renal function and by race/ethnicity of patients.
- Conditions
- Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- NCT05534620
- Testing
- Treosulfan, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- medac GmbH
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Primary Objective Evaluate the efficacy of sitagliptin in reducing the incidence of grade II-IV acute Graft Versus-Host Disease (GvHD) by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell…
- Trial name
- NCT02683525
- Testing
- Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Sherif S. Farag
HIV
HIV Eradication Through Cord-blood Transplantation
Allogeneic hematopoietic cell transplantation from a CCR5 Δ32/Δ32 unrelated donor, performed for the first time in the "Berlin patient", provides the only evidence to date of long-term control of HIV infection.
- Trial name
- HIVECT (NCT02923076)
- Testing
- CCR5 delta32/delta32 cord blood transplantation
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Puerta de Hierro University Hospital
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
This phase II trial studies how well clofarabine and melphalan before a donor stem cell transplant works in treating patients with a decrease in or disappearance of signs and symptoms of myelodysplasia or acute leukemia (disease…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Myelodysplastic Syndrome
- Trial name
- NCT01885689
- Testing
- clofarabine, melphalan, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- City of Hope Medical Center
Nutrition Aspect of Cancer, Stem Cell Transplant Complications
Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients
The use of high-dose radiotherapy, chemotherapy and preventive antibiotics in the preconditioning regimen before allogeneic hematopoietic stem cell transplantation can easily lead to damage to the gastrointestinal mucosa…
- Trial name
- NCT05590091
- Testing
- Parenteral nutrition;Enteral nutrition
- Volunteers
- 106 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Mantle-Cell Lymphoma
Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma
The purpose of this study is to improve the overall survival of Mantle-Cell-Lymphoma (MCL) by a new concept of treatment with primary curative intention consisting of six courses of immunochemotherapy followed by high-dose…
- Trial name
- HD-MCL2003 (NCT00946374)
- Testing
- Immunochemotherapy, High-dose BEAM plus autologous SCT, HLA-identical allogenic SCT
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heidelberg University
Ischemic Cardiomyopathy
A Phase I Study of Allogeneic Myocardium-Derived Mesenchymal Stem Cells (HB1011) in Patients With Ischemic Cardiomyopathy
Ischemic cardiomyopathy occurs when the heart muscle is permanently weakened due to blocked coronary arteries that limit blood flow.
- Trial name
- HEART-1 (NCT07861035)
- Testing
- HB1011 (Allogeneic Myocardium-derived Mesenchymal Stem Cells)
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- HieraBio Inc.
Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
The goal of this clinical research study is to learn if giving romidepsin before and after a stem cell transplant in combination with fludarabine and busulfan can help to control leukemia or lymphoma.
- Conditions
- Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia, T-Lymphoblastic Leukemia/Lymphoma
- Trial name
- NCT02512497
- Testing
- Romidepsin, Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Acute Myeloid Leukemia (AML)
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML
The purpose of this prospective phase III, open-label, randomized multicenter study is to evaluate whether Acute Myeloid Leukemia (AML) elderly patients in Complete Remission (CR) undergoing allogeneic hematopoietic stem cell…
- Trial name
- GITMO-AMLR2 (NCT01191957)
- Testing
- Busulphan plus Cyclophosphamide, Busulphan plus Fludarabine
- Where
- 26 sites in Israel, Italy
- Volunteers
- 252 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Hematopoietic and Lymphoid Cell Neoplasm
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
This phase II trial studies the how well donor stem cell transplant works in treating patients with high risk hematologic malignancies.
- Trial name
- NCT03032783
- Testing
- Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Graft-Versus-Host Disease, Hematological Malignancies
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
The present project is a multicenter phase II trail aiming at comparing which of the two postgrafting immunosuppressive regimens proposed in this study will be best suited to prevent graft-versus-host disease (GVDH).
- Trial name
- NCT01428973
- Testing
- Mycophenolate mofetil, Sirolimus
- Where
- 13 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- University of Liege
Multiple Myeloma and Plasma Cell Neoplasm
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00003195
- Testing
- recombinant interferon alfa, busulfan, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Acute Leukemia, Acute Lymphoblastic Lymphoma
Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)
This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow…
- Trial name
- NCT06803745
- Testing
- 200 cGy or 400 cGy total body irradiation (TBI)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Lymphobkastic Leukemia, Adult
Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if Inotuzumab Ozogamicin works to prevent relapses after transplantation in adult high-risk B-cell precursor acute lymphoblastic leukemia treated with the PETHEMA ALL-2025 protocol.
- Trial name
- INOPOSALO (NCT07862946)
- Testing
- Inotuzumab Ozogamicin (IO)
- Where
- 10 sites in Spain
- Volunteers
- 30 people
- Sponsor
- PETHEMA Foundation
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort.
- Trial name
- NCT06529731
- Testing
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sawa Ito, MD
Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation
FMT In High-Risk Acute GVHD After ALLO HCT
The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) treatment in high-risk acute graft-versus-host disease (GVHD). This research study involves an experimental intervention called FMT.
- Conditions
- Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation, Fecal Microbiota Transplant
- Trial name
- NCT04139577
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for…
- Conditions
- Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT05088356
- Testing
- Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Stanford University
Graft Failure, Stem Cell Transplant Complications
Second Transplantation for Graft Failure
Graft failure is a lethal complication after allogeneic stem cell transplantation, which often need a salvage transplantation. However, the current outcome of second transplantation for graft failure is far from satisfactory.
- Trial name
- NCT03717545
- Testing
- second allogeneic stem cell transplantation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking University People's Hospital
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.